Celestoderm-V cream with Garamycin cream

Country: Armenía

Tungumál: enska

Heimild: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Virkt innihaldsefni:

betamethasone (betamethasone 17-valerate), gentamicin (gentamicin sulfate)

Fáanlegur frá:

Schering-Plough Labo N.V.

ATC númer:

D07CC01

INN (Alþjóðlegt nafn):

betamethasone (betamethasone 17-valerate), gentamicin (gentamicin sulfate)

Skammtar:

1mg/g+ 1mg/g

Lyfjaform:

cream

Einingar í pakka:

aluminium tube 30g

Gerð lyfseðils:

Prescription

Leyfisstaða:

Registered

Leyfisdagur:

2019-03-13

Vara einkenni

1.
NAME
OF
THE
MEDICINAL
PRODUCT
CELESTODERM.VCI
WITH
OARAMYCIN@
International nonproprietary
name:
betamethasone
and
antibiotics.
2.
QUALITATIVE
AND
QUANTITATIVII
COMPOSITION
I
g
of
cream
contains
active
ingredients.'
1
g
of
cream
contain
s
1,220
nrg
betamethasone valerate
equivalent
to
I
rng
of
betamethasone
and
gentamicin
sulfate
equivalent
to
I
mg
(1000
t.U.) of
gentamicin.
excipients:
white soft
paraffin,
cetostearylalcohol,
liquid
paraffin,
macrogol cetostearyl
ether,
sodium dihydrogen
phosphate
dihydrate,
clilorocresol, phosphoric
acid,
sodium
hydroxide/
phosphoric
acid,
purified
water.
3.
PIIARMACEUTICALFORM
Cream.
Description:
homogeneous,
white
to off-white
soft
crearn
without
fbreign
inclusions
Pharmacotherapeutic
group.
Corticosteroids,
dermatological
preparations,r.Qorlicosteroids,
combinations
with
antibiotics.
4.
CLINICAL
PARTICULARS
-"
.
,
;
,;,';10';.
d//}
/.
ol.,xot
f
,
Treatment
of
skin
diseases
requiring
treatment
with
a
potent
glucocorticoid
in the
presence
of
superinfection
with
gentam
icin-suscepti ble
organ
i
sms
4.2
Posology
and method
of
administration
Posolosy:
Cream
is
applied
2'3
times
daily.
The
frequency
nray
be
reduced
as
the
condition
improves.
Method
of
adminisration
:
A
thin
film
of
Cream
should
be
applied
to
the
affected
areas
of
skin,
The
method
of
administration
should
be
adjusted
to
the skin
type
and
stage
of
the
disease.
Crearn
is recommended
in
particular
for
greasy
skin,
weeping,
itching,
burning
and
seborrheic
skin
diseases,
in
acute
stage.
Duration
of
use:
The
duration
of
treatment
with
creafir
should
not
exceed 7-10
days
(7
days
in
children)
because
of
the
gentamicin
content.
As
soon
as
rnedically
confirmed
that
combined
therapy
is no
longer
necessary
(i.e.,
either
a
dermatosis
requiring
a
strong-acting
gh.rcocorticoid
or
a
superinfection
with
gentarnicin-
susceptible
organisms
is
no
longer
present),
tleatment should
be
continued
on
the
basis
of
single-agent
therapy
with
a
glucocorticoid
(possib[y
a
weaker-acting
glucocorticoid)
or
with
an
antibiotic.
Mild
cases
usuall